news_image.jpg

Gender-affirming therapy using medroxyprogesterone acetate has few side affects

10 May 2019



According to research published in the Journal of Clinical Endocrinology and Metabolism, the use of medroxyprogesterone acetate in transgender women significantly reduces testosterone without impacting estradiol levels.

Endocrinology Advisor



Issue 45 - Autumn 2019 - ESPE 2019 in Vienna

Latest Newsletter

Issue 45 - Autumn 2019 - ESPE 2019 in Vienna

Issue 45 - Autumn 2019 - ESPE 2019 in Vienna

Newsletter Archive

Previous newsletters can be viewed and downloaded from the archive.

Newsletter Archive